Search results
Results from the WOW.Com Content Network
Canada Drugs otherwise known as CanadaDrugs.com, was an online pharmacy based in Winnipeg, Manitoba. It was started in 2001 by former Manitoba pharmacist Kristjan Thorkelson as an offshoot of a chain of four local pharmacies, called The Prescription Shop , in Winnipeg.
Established in 2002, the Canadian International Pharmacy Association ("CIPA") is a Canadian association of licensed pharmacy businesses offering mail order pharmacy services to Canadian and international patients. CIPA members sell pharmaceuticals and maintenance medications to individuals upon receipt of a valid prescription.
The Controlled Drugs and Substances Act (French: Loi réglementant certaines drogues et autres substances) is Canada's federal drug control statute. Passed in 1996 under Prime Minister Jean Chrétien's government, it repeals the Narcotic Control Act and Parts III and IV of the Food and Drugs Act, and establishes eight Schedules of controlled substances and two Classes of precursors.
The debate over the reimportation of pharmaceuticals has reemerged with the state of Florida being granted approval by the FDA to import prescription drugs from Canada.
The application dossier for marketing authorisation is called a New Drug Application (NDA) in the USA or Marketing Authorisation Application (MAA) in the European Union and other countries, or simply registration dossier. This contains data proving that the drug has quality, efficacy and safety properties suitable for the intended use ...
Canada's Drug Agency (CDA; French: L’Agence des médicaments du Canada, AMC) is a pan-Canadian health organization responsible for coordinating and aligning drug ...
Drug companies have argued that Medicare’s price negotiations could chill their research and development, leading to fewer new medications coming to market. This story has been updated with ...
Priority review status can apply both to drugs that are used to treat serious diseases and to drugs for less serious illnesses. The distinction between priority and standard review times is that additional FDA attention and resources will be directed to drugs that have the potential to provide significant advances in treatment.